Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter of Fiscal Year 2021 Results on February 17, 2021
Elite Pharmaceuticals (ELTP) will announce its third-quarter financial results on February 16, 2021. A conference call is scheduled for February 17, 2021, at 11:30 AM EST to discuss the results and provide a business update. The call will address questions submitted by stockholders. Elite Pharmaceuticals focuses on developing niche generic products and operates a cGMP and DEA registered facility in Northvale, NJ. Forward-looking statements in the release highlight potential risks and uncertainties.
- None.
- None.
Financials for Third Quarter of Fiscal Year 2021 ended December 31, 2020 will be released on February 16, 2021
NORTHVALE, NJ / ACCESSWIRE / February 10, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2021 third-quarter financial results on Tuesday, February 16, 2021. Elite's management will host a live conference call Wednesday, February 17 at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company prior to the call.
Date: Time: Dial- in numbers:
Questions:
| February 17, 2021 11:30 AM EST 1-800-346-7359 (domestic) 98840 dianne@elitepharma.com |
The financial statements can be viewed for Elite's Fiscal Year 2021 Third Quarter Report on Form 10-Q here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products that have been licensed to Lannett Company, Glenmark Pharmaceuticals, Inc., and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance, or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance, or achievements of Elite to be materially different from the results, performance, or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.
CONTACT:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
SOURCE: Elite Pharmaceuticals, Inc.
View source version on accesswire.com:
https://www.accesswire.com/628821/Elite-Pharmaceuticals-Inc-to-Host-Conference-Call-to-Provide-Corporate-Update-and-Discuss-Third-Quarter-of-Fiscal-Year-2021-Results-on-February-17-2021
FAQ
When will Elite Pharmaceuticals release its third-quarter financial results for 2021?
What is the date and time for Elite Pharmaceuticals' conference call?
What topics will be discussed during the Elite Pharmaceuticals conference call?
How can stockholders submit questions for the conference call?
What is the focus of Elite Pharmaceuticals as a company?
